Framework
- ENQA (the European Association for Quality Assurance in Higher Education) disseminates information, experiences and good practices in the field of quality assurance (QA) in higher education to European QA agencies, public authorities and higher education institutions. ENQA was established in 2000 to promote European co-operation in the field of quality assurance.
- EMTRAIN has an affiliate status within ENQA since June 2011.
- OECD Global Science Forum (OECD-GSF), Working Group to Facilitate International Cooperation in Non-Commercial Clinical Trials, Final report - Draft as of October 20, 2011
- OECD-GSF, Working Group to Facilitate International Cooperation in Non-Commercial Clinical Trials, Contribution from Education and Training, Subgroup 2: Infrastructure Patient Involvement
- Towards Standards for PhD Education in Biomedicine and Health Sciences, A position paper from ORPHEUS, Prepared during ORPHEUS 2009: Fourth European Conference 23-25 April 2009
- Standards for PhD Education in Biomedicine and Health Sciences in Europe, A proposal from ORPHEUS – AMSE – WFME, Aarhus University Press, Denmark 2012
ESFRI BMS Partners
ELIXIR: Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Latvia, Netherlands, Poland, Slovenia, Spain, Sweden, Switzerland, United Kingdom;
BBMRI: Austria, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Malta, Netherlands, Norway, Spain, Sweden, United Kingdom;
INSTRUCT: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom;
INFRAFRONTIER: Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Portugal, Spain, Sweden, United Kingdom, and Canada;
EATRIS: Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom.
|
MUW (ECRIN partner)
The Medizinische Universitaet Wien is a contracting partner of the European Clinical Research Infrastructures Network (ECRIN) Consortium Agreement and Managing Entity of the European Medicines Research Training Network (EMTRAIN)
ECRIN
ELIXIR
BBMRI-ERIC
Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC) - Austria
Instruct
Instruct is the dynamic hub of structural biology providing an integrated infrastructure of cutting-edge technology, scientific expertise and pioneering training
Infrafrontier
EATRIS
EMTRAIN Articles
EMTRAIN
EMTRAIN (European Medicines Research Training Network)
Newsletter
- EMTRAIN Newsletter, 16th Edition, May-October 2014
- EMTRAIN Newsletter, 15th Edition, January-April 2014
- EMTRAIN Newsletter, 14th Edition, July-December 2013
- EMTRAIN Newsletter, 13th Edition, April/May/June 2013
- EMTRAIN Newsletter, 12th Edition, January/February/March 2013
- EMTRAIN Newsletter, 11th Edition, October/November/December 2012
- EMTRAIN Newsletter, 10th Edition, July/August/September 2012
- EMTRAIN Newsletter, 9th Edition, May/June 2012
- EMTRAIN Newsletter, 8th Edition, March/April 2012
- EMTRAIN Newsletter, 7th Edition, January/February 2012
- EMTRAIN Newsletter, 6th Edition, November/December 2011
- EMTRAIN Newsletter, 5th Edition, September/October 2011
- EMTRAIN Newsletter, 4th Edition, July/August 2011
- EMTRAIN Newsletter, 3rd Edition, June 2011
- EMTRAIN Newsletter, 2nd Edition, May 2011
- EMTRAIN Newsletter, 1st Edition, April 2011
WP 1 Management
To efficiently manage and to coordinate the activities of work packages in EMTRAIN through the activity of the Project Office (based at the Medizinische Universitaet Wien) including workflow and budget; to ensure timely release of deliverables.
WP Leader: MUW and AstraZeneca
Coordinating Persons
WP 2 Strategy and Pan-European Expansion
The WP2 will deliver strategic documents regarding the planning, development, implementation and extension of the platform, and adapt those to emerging concepts and techniques, to the evaluations and to the requirements of the quality assurance system. It will act as the secretariat of the Strategic Coordination Board, thereby taking into account the needs of the other IMI E&T Topics. It will take advantage of the activity of the Managing Coordination Board, providing input on ongoing activities and needs within the work packages, and consider input given by the Network Committee and the External Advisory Board, with the support of the mapping developed by WP3.
WP Leader: ECRIN (INSERM) and AstraZeneca
Coordinating Persons
WP 3 Mapping
WP3 objectives are the management of tools for the mapping work to be undertaken by WPs 5-8 and the management of a “gap team” that makes recommendations based on comparative analysis of gaps identified by WPs 5-8. These tools and the gap team will also be made available for the other IMI E&T topics.
WP Leader: Boehringer Ingelheim and BBMRI (University of Manchester)
Coordinating Persons
WP 4 Accreditation/Harmonisation/National Implementation
Develop a platform for harmonisation and accreditation for Education and Training programmes supported by the Bologna Process by which the European Higher Education Area will be established in 2010. Extension and harmonisation of educational and training programmes (WP5-7) within the European countries and harmonisation of programmes between private and public partners. National implementation of developed programmes (WP5-7) will allow sustainability of the project.
WP4 was merged with WP7 in 2011 to develop the LifeTrain framework (http://www.emtrain.eu/index.php/news/174-lifetrain-off-to-a-flying-start).
WP Leader: ECRIN (Karolinska University Hospital), INSTRUCT (University of Oxford), Lundbeck and Bayer Schering
Coordinating Persons
WP 5 Master programmes
The Objectives of WP5 are concerned with higher education to the Master’s degree level. WP5 will identify, catalogue and prioritise relevant programmes in European centres of excellence, compare their content with IMI E&T standards, develop and elicit new content in conjunction with other E&T Topics (current and/or future) and make recommendations based on this work.
WP Leader: BBMRI (University of Manchester), Infrafrontier (GIE-CERBM) and Roche
Coordinating Persons
WP 6 PhD programmes
Identify and catalogue existing Public-Private Partnership PhD programmes in the relevant topics for drug development, in European centres of excellence, including contents, requirements and contracts. Develop a standardised framework contract for Public Private Partnership’ PhD students. Recruit all new IMI PhD students (from scientific IMI topics and from E&T Topics where relevant), into a PhD Network, facilitate communication across the Network, track progress and build a PhD alumni. Support PhD students in achieving mobility between academia and industry. Provide training for the drug development process and business awareness, resulting in a cohort of industry-aware PhD scientists to stimulate improved future industry-academia interactions including careers in the industry/academia. Students from outside the EU can be enrolled into the European training programme and thus broaden the base of scientists working in the EU.
WP Leader: EATRIS (Karolinska Institute), Infrafrontier (GIE-CERBM) and UCB
Coordinating Persons
WP 7 Continuing Professional Development
The purpose of this work package is to coordinate and facilitate the future harmonization of professional development programmes for stakeholders in pharmaceutical medicines research. We will do this by assessing the state of the art in terms of currently available continuing professional development programmes, creating a registry of what is available, and identifying gaps and synergies. The central registry and resulting analysis will provide a resource that can be used by IMI E&T topics and future call topics to develop CPD programmes that can be applied throughout Europe and that facilitate the mobility of professionals in pharmaceutical medicines research, both geographically and between academia and industry.
WP7 was merged with WP4 in 2011 to develop the LifeTrain framework (http://www.emtrain.eu/index.php/news/174-lifetrain-off-to-a-flying-start).
WP Leader: ELIXIR (EMBL-EBI) and Pfizer (discontinued)
Coordinating Persons
WP 8 Learning and teaching concepts and methodology
The purpose of this workpackage is to assess the state of the art in terms of currently available teaching methodologies and tools (including, but not limited to, electronic learning and teaching platforms as well as participant tracking), with the aim of applying them effectively to a future European training platform in drug development for all relevant stakeholders in medicines research. Specific attention will be given to available or future open source solutions.
The ultimate goal is to use these technologies, and new ones as they are developed, to train a flexible and mobile workforce for European medicines research. By creating a central catalogue of tools, resources and methods that can be used by IMI E&T Programmes and future programmes to share best working practice, we aim to stimulate the integration of new learning and teaching methodologies into their respective training programmes. Once we have completed this initial information-gathering exercise, we will work with representatives from the other IMI education and training call topics to determine:
- how to incorporate effective and relevant teaching methodologies and tools into the programmes that are being developed
- how to maintain a ‘teaching technology and methodology’ watch to ensure that future IMI education and training initiatives keep pace with developments in pedagogy
- how to develop new tools if necessary for use by current and future IMI call topics.
WP Leader: ELIXIR (EMBL-EBI) and Helmholtz Centre for Infection Research and Sanofi-Aventis
Coordinating Persons
WP 9 Information, communication and dissemination
The coordination, communication and dissemination of relevant information among all participants in EMTRAIN and all other IMI topics. Ensure the coordination, promotion and advertising of IMI JU E&T programmes to the target audiences such as students, universities, companies, researchers, the public, policy makers, patient organizations, journalists, healthcare professionals, learned societies, professional associations, health authorities, other pharmaceutical medicine stakeholders as well as national ministries, European Commission and participants of all IMI JU E&T Topics.
WP Leader: Janssen and ECRIN (MUW)
Coordinating Persons
EMTRAIN Mission
EMTRAIN Core Team
Completion status
Deadline: 30.Sep.2016